NCT05096039 - Role of Sacubitril/Valsartan in Improving Provider Performance in Managing Heart Failure Under Medicare Alternative Payment Models | Biotech Hunter

Enrollment

1,614,719

Participants

Timeline

Start Date

April 10, 2020

Primary Completion Date

September 30, 2020

Study Completion Date

September 30, 2020

Conditions

Heart Failure

Interventions

DRUG

Sacubitril/valsartan

Beneficiaries with one or more prescription claim with an NDC for sacubitril/valsartan (from the PDE file) during the 90-day episode window. Patients who met these criteria were assigned a value of '1'; patients that did not meet these criteria were assigned a value of '0'

DRUG

ACEI or ARB and no sacubitril/valsartan

Beneficiaries with one or more prescription claim with an NDC for any ACEI/ARB and no prescription claims for sacubitril/valsartan during the 90-day episode window. Patients who met these criteria were assigned a value of '1'; patients that did not meet these criteria were assigned a value of '0'

Trial Locations (1)

07936

Novartis Pharmaceuticals, East Hanover